Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker KURA
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Oct 27, 2026 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | BlackRock, Inc. | 7.91M | 8.9% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Aaron Cowen | 8.58M | 9.7% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Averill Master Fund, Ltd. | 7.81M | 8.8% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Montanova Capital, LLC | 8.58M | 9.7% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Steven Boyd | 3.74M | 4.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Armistice Capital, LLC | 3.74M | 4.2% | SCHEDULE 13G/A ↗ |
| Apr 30, 2026 | SCHEDULE 13G | KURA Kura Oncology, Inc. | Vanguard Capital Management | 4.43M | 5.0% | SCHEDULE 13G ↗ |
| Mar 27, 2026 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | The Vanguard Group | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Steven Boyd | 4.94M | 5.7% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Armistice Capital, LLC | 4.94M | 5.7% | SCHEDULE 13G/A ↗ |
| Feb 9, 2026 | SCHEDULE 13G | KURA Kura Oncology, Inc. | State Street Corporation | 4.93M | 5.7% | SCHEDULE 13G ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Steven Boyd | 4.67M | 5.4% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Armistice Capital, LLC | 4.67M | 5.4% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Mark N. Lampert | 8.68M | 10.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | BVF Inc/Il | 8.68M | 10.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | BVF Partners L P/Il | 8.68M | 10.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | BVF GP Holdings LLC | 8.06M | 9.3% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | BVF Partners OS Ltd. | 446,606 | 0.5% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Biotechnology Value Trading Fund OS LP | 446,606 | 0.5% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | BVF II GP LLC | 3.64M | 4.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Biotechnology Value Fund II LP | 3.64M | 4.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | BVF I GP LLC | 4.42M | 5.1% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Biotechnology Value Fund L P | 4.42M | 5.1% | SCHEDULE 13G/A ↗ |
| Aug 15, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Steven Boyd | 6.20M | 7.1% | SCHEDULE 13G/A ↗ |
| Aug 15, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Armistice Capital, LLC | 6.20M | 7.1% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | EcoR1 Capital Fund Qualified, L.P. | 3.94M | 4.5% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Oleg Nodelman | 4.20M | 4.8% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | EcoR1 Capital, LLC | 4.20M | 4.8% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | RA Capital Healthcare Fund, L.P. | 4.00M | 4.9% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Rajeev Shah | 4.00M | 4.9% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Peter Kolchinsky | 4.00M | 4.9% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | RA Capital Management, L.P. | 4.00M | 4.9% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Steven Boyd | 6.57M | 7.6% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Armistice Capital, LLC | 6.57M | 7.6% | SCHEDULE 13G/A ↗ |
| May 2, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Aaron Cowen | 7.56M | 9.4% | SCHEDULE 13G/A ↗ |
| May 2, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Averill Master Fund, Ltd. | 6.92M | 8.6% | SCHEDULE 13G/A ↗ |
| May 2, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Suvretta Capital Management, LLC | 7.56M | 9.4% | SCHEDULE 13G/A ↗ |
| Apr 17, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | BlackRock, Inc. | 6.33M | 7.8% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G | KURA Kura Oncology, Inc. | Steven Boyd | 5.80M | 7.5% | SCHEDULE 13G ↗ |
| Feb 14, 2025 | SCHEDULE 13G | KURA Kura Oncology, Inc. | Armistice Capital, LLC | 5.80M | 7.5% | SCHEDULE 13G ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Paradigm BioCapital International Fund Ltd. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Senai Asefaw, M.D. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Paradigm BioCapital Advisors GP LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Paradigm BioCapital Advisors LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 13, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | James E. Flynn | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 13, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Deerfield Partners, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 13, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Deerfield Management Company, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 13, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Deerfield Mgmt, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 13, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Aaron Cowen | 5.20M | 6.7% | SCHEDULE 13G/A ↗ |
| Feb 13, 2025 | SCHEDULE 13G/A (amended) | KURA Kura Oncology, Inc. | Averill Master Fund, Ltd. | 4.59M | 5.9% | SCHEDULE 13G/A ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 10:33 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances